Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:CCCCNASDAQ:NMRANASDAQ:TROV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.50+0.7%$1.30$0.87▼$6.78$148.99M0.71831,665 shs362,911 shsCCCCC4 Therapeutics$1.52-1.3%$1.49$1.09▼$7.66$109.35M2.931.32 million shs676,705 shsNMRANeumora Therapeutics$0.80-1.1%$0.76$0.61▼$17.19$130.68M2.731.52 million shs673,280 shsTROVCardiff Oncology$3.16+1.9%$16.75$0.70▼$3.46$34.80M1.04648,892 shs577,316 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+0.67%+2.74%+19.05%+16.28%-65.28%CCCCC4 Therapeutics-1.30%+5.56%+16.92%-13.14%-67.17%NMRANeumora Therapeutics-1.05%+2.49%+14.20%-22.39%-90.70%TROVCardiff Oncology-3.13%+2.65%+2.31%-9.88%+32.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.3738 of 5 stars3.11.00.04.51.22.50.0CCCCC4 Therapeutics2.2548 of 5 stars3.32.00.00.02.71.70.6NMRANeumora Therapeutics2.0264 of 5 stars3.10.00.00.02.32.51.3TROVCardiff OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00166.67% UpsideCCCCC4 Therapeutics 2.50Moderate Buy$12.00689.47% UpsideNMRANeumora Therapeutics 2.22Hold$9.291,061.59% UpsideTROVCardiff Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TROV, ALEC, CCCC, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.004/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/2/2025NMRANeumora TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.49N/AN/A$1.29 per share1.16CCCCC4 Therapeutics$35.58M3.03N/AN/A$3.06 per share0.50NMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ATROVCardiff Oncology$250K139.18N/AN/A$0.94 per share3.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)CCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.61N/AN/AN/AN/A-84.79%-77.57%8/5/2025 (Estimated)TROVCardiff Oncology-$16.41M-$2.80N/A∞N/A-3,688.31%-202.00%-122.92%N/ALatest TROV, ALEC, CCCC, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ATROVCardiff OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34CCCCC4 TherapeuticsN/A5.705.70NMRANeumora TherapeuticsN/A8.988.98TROVCardiff Oncology0.122.372.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%CCCCC4 Therapeutics78.81%NMRANeumora Therapeutics47.65%TROVCardiff Oncology9.99%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%CCCCC4 Therapeutics8.73%NMRANeumora Therapeutics26.80%TROVCardiff Oncology0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableNMRANeumora Therapeutics108161.75 million118.40 millionOptionableTROVCardiff OncologyN/A11.01 millionN/ANot OptionableTROV, ALEC, CCCC, and NMRA HeadlinesRecent News About These CompaniesJefferies Initiates Coverage of Cardiff Oncology (CRDF) with Hold RecommendationJune 25 at 4:44 AM | msn.comCardiff Oncology falls after naming new medical chief ahead of key trial readoutJune 17, 2025 | msn.comCardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + PaclitaxelJune 3, 2025 | insidermonkey.comWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 6.08%April 29, 2025 | aaii.comACardiff Oncology announces second patent for onvansertib combinationApril 24, 2025 | markets.businessinsider.comCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23, 2025 | tmcnet.comCardiff Oncology (NASDAQ:CRDF) Stock, Option ChainApril 23, 2025 | benzinga.comIs Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comCardiff Oncology’s Earnings Call: Optimism Amid ChallengesFebruary 28, 2025 | tipranks.comWilliam Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)February 27, 2025 | markets.businessinsider.comWhy Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 15.07%January 31, 2025 | aaii.comACardiff Oncology Inc (CRDF) Stock: More Robust Than the Numbers Suggest?December 14, 2024 | bovnews.comBCardiff Oncology Inc (CRDF) Stock: Surpassing Expectations in the Market?December 14, 2024 | bovnews.comBCardiff Oncology announces positive colorectal data and $40m stock oversubscriptionDecember 11, 2024 | msn.comCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offeringDecember 10, 2024 | endpts.comECardiff stock soars on onvansertib data, $40M direct offeringDecember 10, 2024 | msn.comCardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingDecember 10, 2024 | tmcnet.comStock Surge, Strong Data: Is Cardiff Oncology (CRDF) on the Brink of a Major Breakthrough?December 10, 2024 | bovnews.comBCardiff Oncology Reports Positive Q3 2024 Results and Clinical ProgressNovember 9, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTROV, ALEC, CCCC, and NMRA Company DescriptionsAlector NASDAQ:ALEC$1.50 +0.01 (+0.67%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.54 +0.04 (+2.60%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.C4 Therapeutics NASDAQ:CCCC$1.52 -0.02 (-1.30%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.54 +0.02 (+1.32%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Neumora Therapeutics NASDAQ:NMRA$0.80 -0.01 (-1.05%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.82 +0.02 (+3.08%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Cardiff Oncology NASDAQ:TROVCardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
